X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-14 | MDGL | Waltermire Robert E. | SVP, Chief Pharma Dev. | S - Sale+OE | $280.00 | -1,900 | 5,500 | -26% | -$532,000 | |||||
| D | 2024-06-12 | MDGL | Waltermire Robert E. | SVP, Chief Pharma Dev. | S - Sale+OE | $285.00 | -2,000 | 5,500 | -27% | -$570,000 | |||||
2024-05-21 | MDGL | Waltermire Robert E. | SVP, Chief Pharma Dev. | S - Sale | $231.34 | -1,036 | 5,500 | -16% | -$239,668 | ||||||
| DM | 2023-12-14 | MDGL | Waltermire Robert E. | SVP, Chief Pharma Dev. | S - Sale+OE | $235.50 | -4,000 | 5,667 | -41% | -$942,000 | |||||
| DM | 2023-12-12 | MDGL | Waltermire Robert E. | SVP, Chief Pharma Dev. | S - Sale+OE | $222.82 | -3,800 | 5,667 | -40% | -$846,700 | |||||
| DM | 2023-02-28 | MDGL | Waltermire Robert E. | SVP, Chief Pharma Dev. | S - Sale+OE | $273.24 | -10,000 | 5,667 | -64% | -$2,732,438 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |